The leadership team at Phesi has been driving the future of pharmaceutical R&D for over a decade, offering unique perspectives on the optimal role of digital technologies, the importance of building service organizations around new technology, and an overall understanding of how the industry needs to transform.
Gen Li is a pharmaceutical industry leader with a passion to improve patients’ lives. Prior to founding Phesi in 2007, Dr. Li was Head of Productivity for Pfizer Worldwide Clinical Development, a position he assumed following Pfizer’s acquisition of Pharmacia, where Dr. Li delivered the first implementation of productivity measurement for clinical development. While at Pharmacia and Pfizer, Dr. Li significantly contributed to the Centre for Medicines Research (CMR) International database for pharmaceutical R&D performance, assuring the collection of key clinical trial parameters as representative of the critical path for delivery. He was also instrumental in creating the KMR productivity mode. Previously, Dr. Li led the creation of the first computer-automated resource management system at Bristol-Myers Squibb. Dr. Li received the prestigious Upjohn Award from Pfizer/Pharmacia. He earned his Ph.D. in Biochemistry from Beijing University, and an MBA from the Johnson Graduate School of Management at Cornell University.
Jonathan Peachey is an industry expert who has led business and IT transformation across pharmaceutical R&D for 25 years. Jonathan came to Phesi after serving as a Board Director at Kinapse, where he transformed the advisory and outsourcing delivery model for life sciences companies. Previously, Jonathan delivered business transformation for IBM’s EU pharmaceutical R&D consulting practice. Jonathan worked as a clinical Program Leader at GSK, Pfizer and BMS. Jonathan’s demonstrated capabilities span strategy, business and IT management, performance improvement and solution design, through to implementation. Jonathan holds a first class honours degree and an Advanced Strategy diploma from Saїd Business School, Oxford University.
Paul Chew is a board-certified cardiologist and internist, serving most recently as Chief Medical Officer for Omada Health, a Silicon Valley-based digital therapeutics company aimed at preventing chronic disease. At Omada, Dr. Chew and his team launched the largest randomized clinical trial in digital therapeutics. Dr. Chew has also held several leadership positions at major pharmaceutical companies. At Sanofi, he served as Senior Vice-President, Global Chief Medical Officer in Paris, and U.S. R&D Head, and at Bristol-Myers Squibb he led the clinical launch of Glucophage® (metformin) in the U.S. and Europe. Dr. Chew is currently on the Board of Trustees for the U.S. Pharmacopeial Convention, which develops and publishes quality standards for drug substances, drug products, excipients, and dietary supplements in the USP–National Formulary (USP–NF), and is recognized by the FDA and 140 countries around the world. Dr. Chew spent 22 years at Johns Hopkins where he received his undergraduate and medical education, served his Osler medical residency, and was a member of the interventional cardiology faculty, holding joint faculty appointments in Radiology and Cardiology.
Otis Johnson is Phesi’s chief commercial officer (CCO), responsible for leading the company’s marketing and business development activities. A 20-year veteran of the pharmaceutical industry, Otis was most recently a vice president at ICON Clinical Research, and before that he was vice president of clinical research at Syneos (formerly inVentiv Health). At both of those major clinical research organizations, Otis was instrumental in overhauling the companies’ feasibility groups, led numerous restructurings and growth plans, and managed technology transformations and other key initiatives, winning several awards in the process. Otis started his career doing basic research in an immunology lab at NYU School of Medicine, then transitioned to clinical research at Merck, where he spent a total of 13 years in various roles including associate director of clinical research and manager of global trial optimization. Otis has a B.S. degree in Medical Laboratory Sciences from Hunter College, a Master of Public Administration (MPA) degree in Health Policy and Management from New York University, and a Ph.D. in Management from Walden University, with a specialization in Leadership and Organizational Change. He also recently completed a certification course at MIT in Artificial Intelligence Strategy: Implications for Business.
Guoqiang Wu is a distinguished engineer with broad IT experience spanning software development, system engineering, and solution architecture. Guoqiang strives to combine state-of-the-art technology and innovative thinking to meet business challenges. Prior to joining Phesi, Guoqiang led the design and implementation of business-critical solutions at Microsoft, where he earned an Engineering Excellence award, and at McKesson, where he also received an award for Excellence in Technology. During his 12-year tenure at Microsoft, Guoqiang built innovative business intelligence solutions and applied his data analytics expertise to transform the life sciences industry. Guoqiang holds a MS degree in Computer Science from North Carolina State University and a MS degree in Chemistry from Beijing University.